Aclaris therapeutics announces proposed settlement and settlement hearing of stockholder derivative action

Wayne, pa., aug. 27, 2021 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “settlement hearing”) will be held on november 30, 2021 at 11:00 a.m. et, before the honorable lewis j. liman at the u.s. district court for the southern district of new york, 500 pearl street, new york, ny 10007 (the “court”) in the matter of in re aclaris therapeutics, inc. derivative litigation, lead case no. 1:19-cv-10641-ljl (the “consolidated derivative action”).
ACRS Ratings Summary
ACRS Quant Ranking